Tissue expander breast reconstruction outcomes following postmastectomy radiation therapy in the era of neoadjuvant chemotherapy
Padilla O., Jairam M., Yen A., Choi J., Buss E., Chin C.
Retrospective Study with a reported sample of 74, published in Front Oncol (2025) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Retrospective Study
- Journal
- Front Oncol (2025)
- Reported sample size
- 74
- Source database
- Europe PMC
- PMID
- 40963866
- PMCID
- PMC12436492
- DOI
- 10.3389/fonc.2025.1636472
Abstract (original English)
Background Optimal sequencing of mastectomy, tissue expander breast reconstruction (TE-BR), chemotherapy, and post-mastectomy radiotherapy (PMRT) remains unclear. While PMRT is known to impact TE-BR outcomes, limited data exist comparing outcomes between patients who also receive neoadjuvant chemotherapy (NAC) versus adjuvant chemotherapy (AC). Methods A retrospective review of 126 patients diagnosed with invasive breast carcinoma who underwent mastectomy, TE-BR, and PMRT between 2001 and 2017 was conducted. Patients were stratified into NAC (n=74) and AC (n=52) cohorts. Logistic regression and Kaplan-Meier analyses evaluated TE-BR failure rates, completion rates, and radiation toxicity. Multivariate Cox proportional hazard regression modeled TE-BR failure probability. Results TE-BR failure rates were significantly higher in the NAC group (44.6% at a median of 18.7 months) compared to the AC group (26.9% at 23.2 months, p=0.041). Moreover, NAC was associated with increased adverse events and lower TE-BR completion rates (both p=0.001). Univariate analysis identified NAC (p=0.007) and acute RT toxicity (p Conclusion Our study is the first to report TE-BR outcomes in women who undergo NAC versus AC in the context of PMRT. Our findings indicate inferior TE-BR outcomes following NAC when PMRT is delivered, emphasizing the importance of shared decision-making between patients and do
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • Without an adequate control group, treatment effects cannot be separated from other factors.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.